Recently, SHP2 was found to promote inflammation-driven insulin resistance, and pharmacological SHP2 inhibition in diabetic mice specifically reduced metaflammation and suppressed macrophage activation, thereby enhancing insulin sensitivity in mice (Paccoud et al., 2021). This evidence concerns the gene PTPN11 and Insulin resistance.